SPECIAL FEATURES

CCR 20th Anniversary Commentary

1975  CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel—How Far Science Has Come
Sami I. Bashour and Nuhad K. Ibrahim

CCR Translations

1978  PLEKHA5: A Key to Unlock the Blood–Brain Barrier?
Sylvia C. Eisele, Corey M. Gill, Ganesh M. Shankar, and Priscilla K. Brastianos
See related article, p. 2138

1981  The Yin and Yang of Alloreactivity: Chronic Graft-versus-Host Disease and Leukemia Relapse
Saar Gill
See related article, p. 2020

CCR New Strategies

1984  New Strategies in Glioblastoma: Exploiting the New Biology
Howard A. Fine

Molecular Pathways

1989  Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer
Lynnette Fernandez-Cuesta and Roman K. Thomas

1995  Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy
Efficacy via Reduction in Oxygen Demand
Alexander Lin and Amit Maiti

Reviews

2001  Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?
Bruno Paiva, Noemi Puig, Ramón García-Sanz, and Jesús F. San Miguel on behalf of the Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study groups

2009  Genomic Landscape of Human Papillomavirus–Associated Cancers
Maria Rusan, Yvonne Y. Li, and Peter S. Hammerman

CANCER THERAPY: CLINICAL

2020  Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
See related commentary, p. 1981

PERSONALIZED MEDICINE AND IMAGING

2029  Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns, Mona Martyt-Smith, Skye Simpson, Scott Mead, Marc D. Jones, Jaswinder S. Samra, Anthony J. Gill, Nicole Watson, Vanessa T. Chin, Jeremy L. Humphris, Angela Chou, Belinda Brown, Adrienne Money, Marina Pajic, Sean M. Grimmond, David K. Chang, David Thomas, Lucille Sebastian, Katrina Sjoquist, Sonia Yip, Nick Pavalakis, Ray Aghzari, Sandra Harvey, Peter Grimison, John Simes, and Andrew V. Blank, on behalf of the Australian Pancreatic Cancer Genome Initiative (APCi) and the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (ACITG)

2038  Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy
Ursula Amstutz, Steven M. Offer, Johanna Sistonen, Markus Joerger, Robert B. Diasio, and Carlo R. Largiadèr

2045  Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia
Brian Parkin, Peter Ouillette, Mehmet Yildiz, Kamlai Saiya-Cork, Kerby Shedden, and Sami N. Malek
PRECLINICAL PHARMACOLOGIC EVALUATION OF TAKING NOTCH SIGNALLING WITH A NOTCH2/NOTCH3 CD47 ENHANCES PTEN LOSS IS ASSOCIATED WITH WORSE OUTCOME IN MGMT ANTIGEN-PRESENTING CELLS

Jasdeep K. Saggar and Ian F. Tannock

TARGETED AXL INHIBITION PRIMES CHRONIC LYMPHOCYTIC LEUKEMIA B CELLS TO APOPTOSIS AND SHOWS SYNERGISTIC/ADDITIVE EFFECTS IN COMBINATION WITH BTK INHIBITORS


RAC1/PAK1/P38/MMP-2 AXIS REGULATES ANGIogenesis IN Ovarian Cancer


THERAPY: PRECLINICAL

CD47 ENHANCES IN VITRO FUNCTIONALITY OF ARTIFICIAL ANTIGEN-PRESENTING CELLS

Heiko Bruns, Catherine Bessell, Juan Carlos Varela, Carl Haupt, Jerry Fang, Shirin Pasemann, Andreas Mackensen, Mathias Oelke, Jonathan P. Schneck, Carl Haupt, John Mackey, Dennis J. Slamon, and Michael F. Press

TARGETING NOTCH SIGNALING WITH A NOTCH2/NOTCH3 ANTAGONIST (TAREXTUMAB) INHIBITS TUMOR GROWTH AND DECREASES TUMOR-INITIATING CELLS


PRECLINICAL PHARMACOLOGIC EVALUATION OF PRALTREXATE AND RIMODIPRIN CONFIRMS POTENT SYNERGY OF THE COMBINATION IN A MURINE MODEL OF HUMAN T-CELL LYMPHOMA


BIOLOGY OF HUMAN TUMORS

PLEKHA5 AS A BIOMARKER AND POTENTIAL MEDIATOR OF MELANOMA BRAIN METASTASIS


SEEN related commentary, p. 1978

THE IMPACT OF CLONE SIZE ON THE PROGNOSTIC VALUE OF CHROMOSOME ABERRATIONS BY FLUORESCENCE IN SITU HYBRIDIZATION IN MULTIPLE MYELOMA

Gang An, Zengjun Li, Yu-Tzu Tai, Chirag Acharya, Qian Li, Xiaoxi Qin, Shuhua Yi, Yan Xu, Xiaoian Feng, Chengwen Li, Jiawei Zhao, Lihui Shi, Meirong Zang, Shuhui Deng, Weimei Su, Mu Hao, Dehui Zou, Yaohong Zhao, Junyuan Qi, Tao Cheng, Kun Ru, Jianxiang Wang, Kenneth C. Anderson, and Lugui Qiu

EMERGENCE OF MULTIPLE EGFR EXTRACELLULAR MUTATIONS DURING CETUXIMAB TREATMENT IN COLORECTAL CANCER

Sabrina Arena, Beatriz Bellosillo, Giulia Siravegna, Alejandro Martinez, Israel Cañadas, Luca Lazzari, Noelia Fernuz, Mariangela Russo, Sandra Misale, Iria Gonzalez, Mar Iglesias, Elena Gaviñan, Giorgio Corti, Sebastian Hobor, Giovanni Cisafulli, Marta Salido, Juan Sanchez, Alba Dalmases, Joaquim Bellmunt, Gianni De Fabritiis, Ana Rovira, Federica Di Nicolantonio, Joan Albanell, Alberto Bardelli, and Clara Montagut
Table of Contents

2167  IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma

2177  Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach
Pleun Hombrink, Chopie Hassan, Michel G.D. Kester, Lorenz Jahn, Margot J. Pont, Arnoud H. de Ru, Comelis A.M. van Bergen, Marieke Griffioen, J.H. Frederik Falkenburg, Peter A. van Veelen, and Mirjam H.M. Heemskerk

LETTERS TO THE EDITOR

2187  RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Letter
Steven Sorscher

2188  RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response
Rona Yaeger and Leonard B. Saltz

RETRACTION

2189  Retraction: Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

CORRECTIONS

2190  Correction: Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer

2192  Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

ABOUT THE COVER

The cover shows establishment of blood brain barrier (BBB) tight junctions. Immunofluorescence staining demonstrates ZO-1 expression within the top endothelial layer of an in vitro BBB. For details, see the article by Jilaveanu and colleagues on page 2138 of this issue.